 |
|
|
| |
Darunavir or Atazanavir vs Raltegravir Lipid Changes are unlinked to Ritonavir Exposure: ACTG 5257
|
| |
| |
Reported by Jules Levin
CROI 2014 March 3-6 Boston, MA
CROI: Efficacy and Tolerability of Atazanavir, Raltegravir, or Darunavir with FTC/TDF: ACTG A5257 - (03/05/14)
CROI: First-Line Raltegravir (RAL) + Darunavir/Ritonavir (DRV/r) is Non-inferior to Tenofovir/Emtricitabine (TDF/FTC) + DRV/r: The NEAT 001/ANRS 143 Randomised Trial - (03/05/14)
Ofotokun I1, Ribaudo H2, Na L2, McComsey G3, Cohn SE4, Godfrey C5, Sagar M2, Aweeka F6, Lennox JL1, Currier J7, for the ACTG 5257 protocol team
1Emory University School of Medicine, Department of Medicine, Atlanta, GA, 2Harvard University, Boston, MA, 3Case Western University, Cleveland, OH, 4Northwestern University, Chicago, IL, 5National Institute of Allergy and Infectious Diseases, Bethesda, MD, 6University of California, San Francisco, San Francisco, CA, 7University of California, Los Angeles, Los Angeles, CA.
|
| |
|
|
|
|
|
